Remove tag sales
article thumbnail

STAT+: Steward Health Care has deal to sell doctor network to UnitedHealth

STAT

The proposed sale of the doctors group, called Stewardship Health, is part of Steward’s plan to bolster its national system of 33 hospitals after the Dallas-based company last year fell behind in paying bills and rents. Continue to STAT+ to read the full story…

Hospitals 142
article thumbnail

STAT+: Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps

STAT

The original bill was introduced over concerns that patients may lose access to rare disease drugs if companies halt sales or decide not to invest in developing such medicines.

123
123
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more

STAT

 The announcement concerning the lower-dose starter product came as the company reported 2023 sales rose 36% and operating profit grew 44% at constant exchange rates, driven by massive sales of Wegovy and Ozempic, used to treat diabetes. Novo also projected double-digit growth in sales and operating profit for 2024.

104
104
article thumbnail

STAT+: Pharmalittle: We’re reading about a Senate probe into Novo pricing, a new UTI antibiotic, and more

STAT

Senate Committee on Health, Education, Labor and Pensions is investigating the prices Novo Nordisk charges for its blockbuster medications, Ozempic and Wegovy, which are highly effective at treating diabetes and obesity but carry steep price tags, The New York Times writes. Bernie Sanders (I-Vt.),

Packaging 102
article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Sales calls that now have to start with a phone call are supported by digital and social content straightaway.

article thumbnail

Global (68M) cardiomyopathies market projected to grow to $9.63bn by 2031

Pharmaceutical Technology

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. of sales in 2021 and 2031 respectively. of global cardiomyopathies sales in 2021 and 31.2%

52
article thumbnail

Biogen’s Aduhelm rollout goes from bad to worse

pharmaphorum

Analysts were predicting sales of Biogen’s recently approved Alzheimer’s therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug seems to be going into reverse. million in sales for the drug in the second quarter. Biogen reported $1.6

Insurance 120